Safety and efficacy of TTFields therapy prior and concomitant to radiotherapy in newly diagnosed glioblastoma - the PriCoTTF phase I/II trial

被引：0

作者：

Kebir, Sied ^{[1
]}

Lazaridis, Lazaros ^{[1
]}

Schmidt, Teresa ^{[1
]}

Oster, Christoph ^{[1
]}

Feldheim, Jonas ^{[1
]}

Proescholdt, Martin ^{[2
]}

Hau, Peter ^{[2
]}

Grosu, Anca Ligia ^{[3
]}

Krex, Dietmar ^{[4
]}

Pierscianek, Daniela ^{[5
]}

Sure, Ulrich ^{[5
]}

Scheffler, Bjoern ^{[6
,7
,8
]}

Kleinschnitz, Christoph ^{[1
]}

Stuschke, Martin ^{[9
]}

Glas, Martin ^{[1
]}

机构：

[1] Univ Duisburg Essen, Univ Med Essen, Div Clin Neurooncol, Dept Neurol,Ctr Translat Neuro & Behav Sci C TNBS, Essen, Germany

[2] Univ Med Ctr Regensburg, Dept Neurosurg, Regensburg, Germany

[3] Univ Hosp Freiburg, Dept Radiat Oncol, Freiburg, Germany

[4] Univ Hosp Dresden, Dept Neurosurg, Dresden, Germany

[5] Univ Hosp Essen, Dept Neurosurg & Spine Surg, Essen, Germany

[6] Univ Med Essen, West German Canc Ctr WTZ, DKFZ Div Translat Neurooncol, Essen, Germany

[7] German Canc Consortium DKTK, Partner Site, Essen, Germany

[8] German Canc Res Ctr, Essen, Germany

[9] Univ Hosp Essen, Dept Radiotherapy, Essen, Germany

来源：

STRAHLENTHERAPIE UND ONKOLOGIE | 2023年 / 199卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

VS09-1-jD

引用

页码：S32 / S32

页数：1

共 50 条

[31] Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma
Biau, J.
Thivat, E.
Chautard, E.
Stefan, D.
Boone, M.
Chauffert, B.
Bourgne, C.
Richard, D.
Molnar, I
Levesque, S.
Bellini, R.
Kwiatkowski, F.
Karayan-Tapon, L.
Verrelle, P.
Godfraind, C.
Durando, X.
RADIOTHERAPY AND ONCOLOGY, 2021, 154 : 227 - 234
[32] Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.
Ahluwalia, Manmeet Singh
Reardon, David A.
Abad, Ajay P.
Curry, William T.
Wong, Eric T.
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle
Mechtler, Laszlo
Uhlmann, Erik J.
Ciesielski, Michael J.
Fenstermaker, Robert
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] A PHASE I TRIAL OF TIPIFARNIB WITH RADIATION THERAPY, WITH AND WITHOUT TEMOZOLOMIDE, FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Nghiemphu, Phioanh Leia
Wen, Patrick Y.
Lamborn, Kathleen R.
Drappatz, Jan
Robins, H. Ian
Fink, Karen
Malkin, Mark G.
Lieberman, Frank S.
DeAngelis, Lisa M.
Torres-Trejo, Alejandro
Chang, Susan M.
Abrey, Lauren
Fine, Howard A.
Demopoulos, Alexis
Lassman, Andrew B.
Kesari, Santosh
Mehta, Minesh P.
Prados, Michael D.
Cloughesy, Timothy F.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (05): : 1422 - 1427
[34] PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Reardon, David
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Casucci, Danielle
Mechtler, Laszlo
Uhlmann, Erik
Ciesielski, Michael
Fenstermaker, Robert
NEURO-ONCOLOGY, 2018, 20 : 10 - 11
[35] Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma
Shi, Wenyin
Roberge, David
Kleinberg, Lawrence
Jeyapalan, Suriya A.
Goldlust, Samuel Aaron
Nagpal, Seema
Lustgarten, Leonardo
Combs, Stephanie E.
Nishikawa, Ryo
Reardon, David A.
Grossman, Rachel
Glas, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Ahluwalia, Manmeet
Ciesielski, Michael J.
Reardon, David A.
Abad, Ajay
Curry, William
Wong, Eric
Peereboom, David
Figel, Sheila
Hutson, Alan
Groman, Adrienne
Withers, Henry
Liu, Song
Belal, Ahmed
Qiu, Jingxin
Mogensen, Kathleen
Schilero, Cathy
Khosla, Atulya
Casucci, Danielle
Mechtler, Laszlo
Fenstermaker, Robert
NEURO-ONCOLOGY, 2022, 24 : 66 - 66
[37] Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM)
Stupp, R.
Goldbrunner, R.
Neyns, B.
Schlegel, U.
Clement, P.
Grabenbauer, G. G.
Hegi, E.
Nippgen, J.
Picard, M.
Weller, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[38] Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
Nagane, Motoo
Ichimura, Koichi
Onuki, Ritsuko
Narushima, Daichi
Honda-Kitahara, Mai
Satomi, Kaishi
Tomiyama, Arata
Arai, Yasuhito
Shibata, Tatsuhiro
Narita, Yoshitaka
Uzuka, Takeo
Nakamura, Hideo
Nakada, Mitsutoshi
Arakawa, Yoshiki
Ohnishi, Takanori
Mukasa, Akitake
Tanaka, Shota
Wakabayashi, Toshihiko
Aoki, Tomokazu
Aoki, Shigeki
Shibui, Soichiro
Matsutani, Masao
Ishizawa, Keisuke
Yokoo, Hideaki
Suzuki, Hiroyoshi
Morita, Satoshi
Kato, Mamoru
Nishikawa, Ryo
CANCERS, 2022, 14 (22)
[39] SAFETY AND EFFICACY OF TEMOZOLOMIDE TREATMENT WITH NEWLY DIAGNOSED GLIOBLASTOMA IN JAPAN: A MULTICENTER PHASE II CLINICAL STUDY
Sugiyama, Kazuhiko
Nishikawa, Ryo
Takeshima, Hideo
Nakamura, Hideo
Aoki, Tomokazu
Takahashi, Jun
Takahash, Hideaki
Saito, Akihiko
Sawamura, Yutaka
Kurisu, Kaoru
Matsutani, Masao
NEURO-ONCOLOGY, 2009, 11 (06) : 948 - 948
[40] SYMPTOM BURDEN IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA UNDERGOING RADIOTHERAPY PLUS TEMOZOLOMIDE AND ENZASTAURIN: RESULTS FROM A PHASE I/II TRIAL
Butowski, Nicholas
Parvataneni, Rupa
Nicole, Angelina
Lamborn, Kathleen
Polley, Mei
Clarke, Jennifer
Chang, Susan
Page, Margaretta
Prados, Michael
Liepa, Astra
Shi, P.
Thornton, Donald
NEURO-ONCOLOGY, 2010, 12 : 104 - 104

← 1 2 3 4 5 →